Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATION

Affiliations

• ¹ Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colo. Electronic address: mikewechsler@gmail.com.
• ² University Medical Center Freiburg, Clinic of Pneumology, Department of Medicine, University of Freiburg, Freiburg, Germany.
• ³ Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Mich.
• ⁴ Global Development, Inflammation, R&D, Amgen, Thousand Oaks, Calif.
• ⁵ Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
• ⁶ Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland.
• ⁷ Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Md.
• ⁸ Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
• ⁹ Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Md.